VC
ADVM

Vivo Capital’s Adverum Biotechnologies ADVM Stock Holding History

Vivo Capital’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-833,333
Closed -$5.85M – 41
2024
Q3 		$5.85M Hold
833,333
– – 0.48% 30
2024
Q2 		$833K Sell
833,333
-666,667
-44% -$6.2M 0.08% 39
2024
Q1 		$21.2M Buy
+1,500,000
New +$22.8M 1.67% 14

Other funds holding ADVM

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PWA
Principia Wealth Advisory Dallas, Texas $160M AUM 37.01% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Vivo Capital's ADVM Position: Q4 2024 in Review

Vivo Capital sold out of Adverum Biotechnologies (ADVM) in Q4 2024, closing a stake of 833,333 shares — an estimated $5.85M sold.

Vivo Capital first reported a position in ADVM in Q1 2024 and held it in 3 quarters. The position peaked at $21.2M in Q1 2024. 69 funds tracked by Wall St. Rank hold ADVM as of Q4 2024.

  • Vivo Capital reported no remaining Adverum Biotechnologies position as of Q4 2024 after selling out during the quarter.
  • Vivo Capital sold 833,333 Adverum Biotechnologies shares in Q4 2024, an estimated $5.85M.
  • Vivo Capital first reported a position in Adverum Biotechnologies in Q1 2024 and held it in 3 quarters.
  • Vivo Capital's Adverum Biotechnologies position peaked at $21.2M in Q1 2024.
  • 69 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2024.

Based on Vivo Capital's 13F filing for Q4 2024, filed 13 Feb 2025.